0001415889-24-002412.txt : 20240202 0001415889-24-002412.hdr.sgml : 20240202 20240202212821 ACCESSION NUMBER: 0001415889-24-002412 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Howe Jolanda CENTRAL INDEX KEY: 0001974200 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38981 FILM NUMBER: 24593705 MAIL ADDRESS: STREET 1: C/O MIRUM PHARMACEUTICALS, INC. STREET 2: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mirum Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001759425 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 831281555 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-667-4085 MAIL ADDRESS: STREET 1: 950 TOWER LANE, SUITE 1050 CITY: FOSTER CITY STATE: CA ZIP: 94404 4 1 form4-02032024_020214.xml X0508 4 2024-01-31 0001759425 Mirum Pharmaceuticals, Inc. MIRM 0001974200 Howe Jolanda C/O MIRUM PHARMACEUTICALS, INC. 950 TOWER LANE, SUITE 1050 FOSTER CITY CA 94404 false true false false SVP, GLOBAL CONTROLLER 0 Common Stock 2024-01-31 4 M 0 1772 A 2494 D Common Stock 2024-02-02 4 S 0 735 26.1918 D 1759 D Restricted Stock Units 2024-01-31 4 M 0 1772 0 D Common Stock 1772 3543 D Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024. 1,772 shares vested on January 31, 2024 ; 1,772 shares will vest January 31, 2025 and the remaining 1,771 shares will vest on January 31, 2026. /s/ Judit Ryvkin, Attorney-in-Fact 2024-02-02